Trade Q32 Bio Inc - QTTB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0758 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.0971 |
| Open | 3.0571 |
| 1-Year Change | 420.71% |
| Day's Range | 3.0571 - 3.2571 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 16, 2025 | 3.0971 | -0.0200 | -0.64% | 3.1171 | 3.1571 | 2.9771 |
| Jan 15, 2025 | 3.1471 | 0.1000 | 3.28% | 3.0471 | 3.2371 | 3.0271 |
| Jan 14, 2025 | 3.0371 | -0.0300 | -0.98% | 3.0671 | 3.1671 | 2.9671 |
| Jan 13, 2025 | 3.0571 | -0.2300 | -7.00% | 3.2871 | 3.3171 | 3.0271 |
| Jan 10, 2025 | 3.3371 | 0.1800 | 5.70% | 3.1571 | 3.3471 | 2.9571 |
| Jan 8, 2025 | 3.2571 | -0.1000 | -2.98% | 3.3571 | 3.3971 | 3.1771 |
| Jan 7, 2025 | 3.4971 | -0.0700 | -1.96% | 3.5671 | 3.9071 | 3.4971 |
| Jan 6, 2025 | 3.6171 | -0.2000 | -5.24% | 3.8171 | 4.0071 | 3.5171 |
| Jan 3, 2025 | 3.9071 | 0.5000 | 14.68% | 3.4071 | 3.9571 | 3.2071 |
| Jan 2, 2025 | 3.3671 | -0.0300 | -0.88% | 3.3971 | 3.4471 | 3.2271 |
| Dec 31, 2024 | 3.3971 | 0.2800 | 8.98% | 3.1171 | 3.4571 | 3.0371 |
| Dec 30, 2024 | 3.0871 | -0.1900 | -5.80% | 3.2771 | 3.2771 | 3.0071 |
| Dec 27, 2024 | 3.3171 | -0.1500 | -4.33% | 3.4671 | 3.5971 | 3.2571 |
| Dec 26, 2024 | 3.4871 | 0.3100 | 9.76% | 3.1771 | 3.6671 | 3.1771 |
| Dec 24, 2024 | 3.2371 | -0.0100 | -0.31% | 3.2471 | 3.2971 | 3.1171 |
| Dec 23, 2024 | 3.1771 | -0.3300 | -9.41% | 3.5071 | 3.5071 | 3.1271 |
| Dec 20, 2024 | 3.4671 | 0.1900 | 5.80% | 3.2771 | 3.6971 | 3.1071 |
| Dec 19, 2024 | 3.3271 | 0.2200 | 7.08% | 3.1071 | 3.3771 | 3.0071 |
| Dec 18, 2024 | 3.0571 | -0.3500 | -10.27% | 3.4071 | 3.4671 | 2.9971 |
| Dec 17, 2024 | 3.3671 | -0.0700 | -2.04% | 3.4371 | 3.6271 | 3.3171 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Homology Medicines Company profile
About Homology Medicines Inc
Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene editing across a range of genetic disorders. Its various set of AAVHSCs allows it to target, via a single injection, a range of disease-relevant tissues, including the liver, central nervous system (CNS), peripheral nervous system (PNS), bone marrow, muscle and eye. Its lead product candidate, HMI-102, is a gene therapy for the treatment of adults with phenylketonuria (PKU). Its other gene therapy product development candidates for the treatment of lysosomal storage diseases are HMI-203, for the treatment of mucopolysaccharidosis type II (MPS II) and HMI-202.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Homology Medicines Inc revenues increased from $1.7M to $33.2M. Net loss decreased 37% to $62.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - Balancing val decrease of 13% to $63.1M (expense), General and administrative - Balancing decrease of 1% to $19.8M (expense).
| Industry: | Bio Therapeutic Drugs |
1 Patriots Park
BEDFORD
MASSACHUSETTS 01730-2343
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com